Gyre Therapeutics (NASDAQ:GYRE) COO Sells $78,843.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) COO Weiguo Ye sold 12,820 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total value of $78,843.00. Following the sale, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. The trade was a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Weiguo Ye also recently made the following trade(s):

• On Wednesday, May 20th, Weiguo Ye sold 9,400 shares of Gyre Therapeutics stock. The shares were sold at an average price of $6.15, for a total transaction of $57,810.00.

Gyre Therapeutics Trading Down 1.9%

Shares of NASDAQ GYRE traded down $0.12 during midday trading on Friday, reaching $6.06. 86,973 shares of the stock were exchanged, compared to its average volume of 90,296. The stock has a 50 day moving average price of $7.29 and a 200-day moving average price of $7.61. The company has a market capitalization of $588.00 million, a P/E ratio of -67.33 and a beta of 2.03. Gyre Therapeutics, Inc. has a 52-week low of $5.97 and a 52-week high of $11.61.

Gyre Therapeutics (NASDAQ:GYRE) last released its earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The firm had revenue of $37.20 million during the quarter, compared to analysts’ expectations of $36.30 million. On average, analysts forecast that Gyre Therapeutics, Inc. will post -0.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GYRE has been the topic of several recent analyst reports. Weiss Ratings lowered shares of Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Wall Street Zen downgraded shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, Zacks Research lowered shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Two research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Gyre Therapeutics has a consensus rating of “Hold” and a consensus target price of $17.00.

Institutional Investors Weigh In On Gyre Therapeutics

A number of large investors have recently modified their holdings of GYRE. Goldman Sachs Group Inc. grew its position in Gyre Therapeutics by 72.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 31,108 shares of the company’s stock valued at $220,000 after acquiring an additional 13,074 shares in the last quarter. Alliancebernstein L.P. grew its stake in shares of Gyre Therapeutics by 9.5% during the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after acquiring an additional 1,900 shares in the last quarter. Barclays PLC lifted its stake in shares of Gyre Therapeutics by 38.3% in the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock worth $131,000 after acquiring an additional 5,135 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $111,000. Finally, Wells Fargo & Company MN boosted its stake in shares of Gyre Therapeutics by 132.4% during the 4th quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after buying an additional 7,361 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.